MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Has PD-1 MET Its Match in Hepatocellular Carcinoma? - Gastroenterology
Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
Novartis promising anti-tumor combination therapy - K-Recruiting
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
Novartis beats Merck KGaA to U.S. finish line with targeted lung cancer drug Tabrecta | Fierce Pharma
c-Met inhibitor 1 | ≥99%(HPLC) | c-Met inhibitor | AdooQ®
Novartis' MET inhibitor Tabrecta wins permit for lung cancer in Korea < Pharma < 기사본문 - KBR
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 | Pharmafile
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer | Novartis
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
Novartis pulls ahead of Merck in MET-positive lung cancer race - PMLiVE
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
MET Inhibitors Active in Advanced NSCLC | MedPage Today
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial - Annals of Oncology
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - Journal of Thoracic Oncology
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
FDA approved ALK inhibitors with substantial impact in the field of... | Download Scientific Diagram
